PDCD1 and cancer: In addition to the combination therapy with other therapeutic modalities, the combination of CTLA-4 and PD-1 blockers has been suggested to have a synergistic impact on eliciting the anti-tumor activities and consequently lessening the response rates in cancer patients [196, 197].